PEPCID AC Drug Patent Profile
✉ Email this page to a colleague
When do Pepcid Ac patents expire, and what generic alternatives are available?
Pepcid Ac is a drug marketed by J And J Consumer Inc and is included in three NDAs.
The generic ingredient in PEPCID AC is famotidine. There are eighteen drug master file entries for this compound. One hundred and forty-four suppliers are listed for this compound. Additional details are available on the famotidine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Pepcid Ac
A generic version of PEPCID AC was approved as famotidine by FRESENIUS KABI USA on April 16th, 2001.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for PEPCID AC?
- What are the global sales for PEPCID AC?
- What is Average Wholesale Price for PEPCID AC?
Summary for PEPCID AC
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 3 |
| Finished Product Suppliers / Packagers: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 83 |
| Clinical Trials: | 35 |
| Patent Applications: | 7,161 |
| What excipients (inactive ingredients) are in PEPCID AC? | PEPCID AC excipients list |
| DailyMed Link: | PEPCID AC at DailyMed |
Recent Clinical Trials for PEPCID AC
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Ohio State University Comprehensive Cancer Center | Phase 2/Phase 3 |
| Leidos Life Sciences | Phase 2 |
| United States Department of Defense | Phase 2 |
Pharmacology for PEPCID AC
| Drug Class | Histamine-2 Receptor Antagonist |
| Mechanism of Action | Histamine H2 Receptor Antagonists |
US Patents and Regulatory Information for PEPCID AC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| J And J Consumer Inc | PEPCID AC | famotidine | TABLET, CHEWABLE;ORAL | 020801-001 | Sep 24, 1998 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| J And J Consumer Inc | PEPCID AC | famotidine | TABLET;ORAL | 020902-001 | Aug 5, 1999 | OTC | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| J And J Consumer Inc | PEPCID AC | famotidine | TABLET, CHEWABLE;ORAL | 020801-002 | Dec 17, 2007 | OTC | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| J And J Consumer Inc | PEPCID AC | famotidine | TABLET;ORAL | 020325-001 | Apr 28, 1995 | OTC | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| J And J Consumer Inc | PEPCID AC | famotidine | TABLET;ORAL | 020325-002 | Sep 23, 2003 | OTC | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for PEPCID AC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| J And J Consumer Inc | PEPCID AC | famotidine | TABLET;ORAL | 020902-001 | Aug 5, 1999 | ⤷ Sign Up | ⤷ Sign Up |
| J And J Consumer Inc | PEPCID AC | famotidine | TABLET, CHEWABLE;ORAL | 020801-001 | Sep 24, 1998 | ⤷ Sign Up | ⤷ Sign Up |
| J And J Consumer Inc | PEPCID AC | famotidine | TABLET;ORAL | 020325-001 | Apr 28, 1995 | ⤷ Sign Up | ⤷ Sign Up |
| J And J Consumer Inc | PEPCID AC | famotidine | TABLET;ORAL | 020902-001 | Aug 5, 1999 | ⤷ Sign Up | ⤷ Sign Up |
| J And J Consumer Inc | PEPCID AC | famotidine | TABLET, CHEWABLE;ORAL | 020801-001 | Sep 24, 1998 | ⤷ Sign Up | ⤷ Sign Up |
| J And J Consumer Inc | PEPCID AC | famotidine | TABLET;ORAL | 020325-001 | Apr 28, 1995 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for PEPCID AC
See the table below for patents covering PEPCID AC around the world.
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
